There are some interesting and exciting research projects happening in the world of hearing loss research. Here are just a few of them

Hearing Loss Research Tracker

Hearing Loss Treatment Report

This page tracks new and upcoming treatment options for sensorineural hearing loss (SNHL). What’s in development? What’s promising? What’s available soon? Current topics include stem cell treatment, gene therapy, and more. 

You can subscribe to this page for updates.

Frequency Therapeutics

Sensorineural Hearing Loss Program: FX-322

Inspired by the real-world impact of the most common form of hearing loss.

Pioneering an approach to therapies that may have applications for a broad range of degenerative disease, beginning with sensorineural hearing loss and multiple sclerosis.

FX-322 is designed to treat the underlying cause of sensorineural hearing loss (SNHL) by regenerating hair cells through activation of progenitor cells already present in the cochlea.

UPDATE: Frequency Therapeutics said it will now discontinue the FX-322 development program.


Clinical trial for people with sudden hearing loss

A team of researchers and clinicians in London and Sheffield are looking for participants to take part in a clinical trial of a new drug treatment for sudden hearing loss.

Sudden onset sensorineural hearing loss (SSNHL) is an emergency condition, where there is a rapid loss in hearing, usually in one ear, either instantly or over the course of 3 days. Current treatments, steroid tablets or injections given as soon as possible after the start of hearing loss, help hearing recovery in some patients but not all. There is therefore a need for new and better treatments.

The SeaSHeL Study

National Prospective Cohort Study

There are a number of new treatments being developed for idiopathic (cause unknown) SSNHL based upon recent discoveries in underlying molecular mechanisms. These treatments require rigorous testing in clinical trials before they can become available for clinical use. To allow for such trials to be run effectively, there is an urgent need for information on patient numbers, geographical distribution, demographics, patient and treatment pathways, as well as outcomes.

This study proposes to collect these data through an ENT trainee and Audiologist led nationwide prospective cohort study of adult patients presenting with SSNHL within the National Health Services (NHS). The study will take place at 97 NHS sites across England with Ear, Nose, and Throat (ENT) and Audiology services.

Note: If you see a study on this page that is no longer running or have a suggestion for an additional study to be added, please send an email to:

Thank you.